Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Carregando...
Citações na Scopus
1672
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER MEDICAL ASSOC
Autores
STERNE, Jonathan A. C.
MURTHY, Srinivas
V, Janet Diaz
SLUTSKY, Arthur S.
VILLAR, Jesus
ANGUS, Derek C.
ANNANE, Djillali
BERWANGER, Otavio
CAVALCANTI, Alexandre B.
Citação
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, v.324, n.13, p.1330-1341, 2020
Resumo
IMPORTANCE Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support. OBJECTIVE To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. DESIGN, SETTING, AND PARTICIPANTS Prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were conducted in 12 countries from February 26, 2020, to June 9, 2020, and the date of final follow-up was July 6, 2020. Pooled data were aggregated from the individual trials, overall, and in predefined subgroups. Risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I-2 statistic. The primary analysis was an inverse variance-weighted fixed-effect meta-analysis of overall mortality, with the association between the intervention and mortality quantified using odds ratios (ORs). Random-effects meta-analyses also were conducted (with the Paule-Mandel estimate of heterogeneity and the Hartung-Knapp adjustment) and an inverse variance-weighted fixed-effect analysis using risk ratios. EXPOSURES Patients had been randomized to receive systemic dexamethasone, hydrocortisone, or methylprednisolone (678 patients) or to receive usual care or placebo (1025 patients). MAIN OUTCOMES AND MEASURES The primary outcome measure was all-cause mortality at 28 days after randomization. A secondary outcome was investigator-defined serious adverse events. RESULTS A total of 1703 patients (median age, 60 years [interquartile range, 52-68 years]; 488 [29%] women) were included in the analysis. Risk of bias was assessed as ""low"" for 6 of the 7 mortality results and as ""some concerns"" in 1 trial because of the randomization method. Five trials reported mortality at 28 days, 1 trial at 21 days, and 1 trial at 30 days. There were 222 deaths among the 678 patients randomized to corticosteroids and 425 deaths among the 1025 patients randomized to usual care or placebo (summary OR, 0.66 [95% CI, 0.53-0.82]; P < .001 based on a fixed-effect meta-analysis). There was little inconsistency between the trial results (I-2 = 15.6%; P = .31 for heterogeneity) and the summary OR was 0.70 (95% CI, 0.48-1.01; P = .053) based on the random-effects meta-analysis. The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths). Among the 6 trials that reported serious adverse events, 64 events occurred among 354 patients randomized to corticosteroids and 80 events occurred among 342 patients randomized to usual care or placebo. CONCLUSIONS AND RELEVANCE In this prospective meta-analysis of clinical trials of critically ill patients with COVID-19, administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
Palavras-chave
Referências
- Abate SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235653
- Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022
- Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD
- Annane D, 2019, COCHRANE DB SYST REV, V12
- Annane D, 2017, INTENS CARE MED, V43, P1751, DOI 10.1007/s00134-017-4919-5
- Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815
- [Anonymous], 2020, COVID 19 REP
- DALE DC, 1973, MED CLIN N AM, V57, P1277, DOI 10.1016/S0025-7125(16)32228-3
- Dequin PF, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.16 761, DOI 10.1001/JAMA.2020.16]
- Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
- Fisher DJ, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j573
- Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
- Hartung J, 2001, STAT MED, V20, P3875, DOI 10.1002/sim.1009
- IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25
- Jeronimo Christiane Maria Prado, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1177
- Langan D, 2017, RES SYNTH METHODS, V8, P181, DOI 10.1002/jrsm.1198
- Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
- PAULE RC, 1982, J RES NAT BUR STAND, V87, P377, DOI 10.6028/jres.087.022
- Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
- RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
- Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
- Sterne JAC, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04641-3
- Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
- Thomas J, PROSPECTIVE APPROACH, DOI 10.1002/9781119536604.ch22
- Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021
- Villar J, 2020, CRIT CARE EXPLOR, V2